Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 44

Related Articles by Review for PubMed (Select 20232070)

1.

Novel CSF biomarkers for Alzheimer's disease and mild cognitive impairment.

Hu WT, Chen-Plotkin A, Arnold SE, Grossman M, Clark CM, Shaw LM, Pickering E, Kuhn M, Chen Y, McCluskey L, Elman L, Karlawish J, Hurtig HI, Siderowf A, Lee VM, Soares H, Trojanowski JQ.

Acta Neuropathol. 2010 Jun;119(6):669-78. doi: 10.1007/s00401-010-0667-0. Epub 2010 Mar 16.

2.

Clinical indications for analysis of Alzheimer's disease CSF biomarkers.

Engelborghs S.

Rev Neurol (Paris). 2013 Oct;169(10):709-14. doi: 10.1016/j.neurol.2013.07.024. Epub 2013 Sep 6. Review.

PMID:
24016466
3.

Advances in the detection of Alzheimer's disease-use of cerebrospinal fluid biomarkers.

Sjögren M, Andreasen N, Blennow K.

Clin Chim Acta. 2003 Jun;332(1-2):1-10. Review.

PMID:
12763273
4.

[Use of cerebrospinal fluid (CSF) biomarkers for Alzheimer's type dementia: diagnosis in mild cognitive impairment].

Verhey FR, Visser PJ.

Ned Tijdschr Geneeskd. 2013;157(11):A5596. Review. Dutch.

PMID:
23484512
5.

Core candidate neurochemical and imaging biomarkers of Alzheimer's disease.

Hampel H, Bürger K, Teipel SJ, Bokde AL, Zetterberg H, Blennow K.

Alzheimers Dement. 2008 Jan;4(1):38-48. doi: 10.1016/j.jalz.2007.08.006. Epub 2007 Dec 21. Review.

PMID:
18631949
6.

Biomarker discovery for Alzheimer's disease, frontotemporal lobar degeneration, and Parkinson's disease.

Hu WT, Chen-Plotkin A, Arnold SE, Grossman M, Clark CM, Shaw LM, McCluskey L, Elman L, Karlawish J, Hurtig HI, Siderowf A, Lee VM, Soares H, Trojanowski JQ.

Acta Neuropathol. 2010 Sep;120(3):385-99. doi: 10.1007/s00401-010-0723-9. Epub 2010 Jul 22. Review.

7.

Growth factors and cytokines/chemokines as surrogate biomarkers in cerebrospinal fluid and blood for diagnosing Alzheimer's disease and mild cognitive impairment.

Olson L, Humpel C.

Exp Gerontol. 2010 Jan;45(1):41-6. doi: 10.1016/j.exger.2009.10.011. Epub 2009 Oct 22. Review.

PMID:
19853649
8.

Cerebrospinal fluid biomarkers for diagnosis of Alzheimer's disease: beta-amyloid(1-42), tau, phospho-tau-181 and total protein.

Marksteiner J, Hinterhuber H, Humpel C.

Drugs Today (Barc). 2007 Jun;43(6):423-31. Review.

PMID:
17612711
9.

CSF biomarkers for mild cognitive impairment.

Blennow K.

J Intern Med. 2004 Sep;256(3):224-34. Review.

PMID:
15324365
10.

CSF biomarkers for amyloid and tau pathology in Alzheimer's disease.

Rosenmann H.

J Mol Neurosci. 2012 May;47(1):1-14. doi: 10.1007/s12031-011-9665-5. Epub 2011 Nov 5. Review.

PMID:
22058061
11.

Cerebrospinal fluid biomarkers of Alzheimer's disease in healthy elderly.

Randall C, Mosconi L, de Leon M, Glodzik L.

Front Biosci (Landmark Ed). 2013 Jun 1;18:1150-73. Review.

12.

Peptides and proteins in plasma and cerebrospinal fluid as biomarkers for the prediction, diagnosis, and monitoring of therapeutic efficacy of Alzheimer's disease.

Aluise CD, Sowell RA, Butterfield DA.

Biochim Biophys Acta. 2008 Oct;1782(10):549-58. doi: 10.1016/j.bbadis.2008.07.008. Epub 2008 Aug 7. Review.

13.

Cerebrospinal fluid biomarkers of Alzheimer's disease.

Sui X, Liu J, Yang X.

Neurosci Bull. 2014 Apr;30(2):233-42. doi: 10.1007/s12264-013-1412-1. Epub 2014 Apr 15. Review.

PMID:
24733653
14.

Neurotransmitter measures in the cerebrospinal fluid of patients with Alzheimer's disease: a review.

Strac DS, Muck-Seler D, Pivac N.

Psychiatr Danub. 2015 Mar;27(1):14-24. Review.

15.

Translational proteomics in Alzheimer's disease and related disorders.

Ghidoni R, Paterlini A, Benussi L.

Clin Biochem. 2013 Apr;46(6):480-6. doi: 10.1016/j.clinbiochem.2012.10.012. Epub 2012 Oct 23. Review.

PMID:
23089105
16.

Biomarkers of Alzheimer's disease and mild cognitive impairment: are we there yet?

Turner RS.

Exp Neurol. 2003 Sep;183(1):7-10. Review. No abstract available.

PMID:
12957483
17.

Role of cerebrospinal fluid and plasma biomarkers in the diagnosis of neurodegenerative disorders and mild cognitive impairment.

Gonzalez-Cuyar LF, Sonnen JA, Montine KS, Keene CD, Montine TJ.

Curr Neurol Neurosci Rep. 2011 Oct;11(5):455-63. doi: 10.1007/s11910-011-0212-0. Review.

18.

Strength and weaknesses of cerebrospinal fluid biomarkers in Alzheimer's disease and possible detection of overlaps with frailty process.

Stefani A, Olivola E, Stampanoni Bassi M, Pisani V, Imbriani P, Pisani A, Pierantozzi M.

CNS Neurol Disord Drug Targets. 2013 Jun;12(4):538-46. Review.

PMID:
23574170
19.

Cerebrospinal fluid biomarkers in mild cognitive impairment and dementia.

Sonnen JA, Montine KS, Quinn JF, Breitner JC, Montine TJ.

J Alzheimers Dis. 2010;19(1):301-9. doi: 10.3233/JAD-2010-1236. Review.

20.

Evolution of the diagnostic criteria for degenerative and cognitive disorders.

Lopez OL, McDade E, Riverol M, Becker JT.

Curr Opin Neurol. 2011 Dec;24(6):532-41. doi: 10.1097/WCO.0b013e32834cd45b. Review.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk